Treatment of diploid human fibroblasts with an alkylating mutagen has been shown to induce stable, anchorage-independent cell populations at frequencies (11 X 10-4) consistent with an activating mutation. After treatment of human foreskin fibroblasts with the mutagen benzo[alpyrene (±)anti-7,8-dihydrodiol 9,10-epoxide and selection in soft agar, 17 anchorage-independent clones were isolated and expanded, and their cellular DNA was used to cotransfect NIH 3T3 cells along with pSV2neo. DNA from 11 of the 17 clones induced multiple NIH 3T3 cell tumors in recipient nude mice. Southern blot analyses showed the presence of human Alu repetitive sequences in all of the NIH 3T3 tumor cell DNAs. Intact, human HRAS sequences were observed in 2 of the 11 tumor groups, whereas no hybridization was detected when human KRAS or NRAS probes were used. Slow-migrating ras p21 proteins, consistent with codon 12 mutations, were observed in the same two NIH 3T3 tumor cell groups that contained the human HRAS bands. Genomic DNA from one of these two human anchorage-independent cell populations (clone 21A) was used to enzymatically amplify a portion of exon 1 of the HRAS gene. Direct sequence analysis of the amplified DNA indicated equal presence of a wild-type (GGC) and mutant (GTC) allele of the HRAS gene. The results demonstrate that exposure of normal human cells to a common environmental mutagen yields HRAS GC -+ TA codon 12 transversions that have been commonly observed in human tumors. This oncogene as well as an as yet to be identified oncogene are also shown to stably confer anchorageindependence to human cells.
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The majority of human tumor cells, and particularly those of mesenchymal origin, have the ability to grow in semisolid medium (i.e., anchorage-independent growth; refs. [1] [2] [3] [4] [5] , a phenotype that is rarely observed in nonneoplastic human cells. Treatment of rodent or human fibroblasts with mutagens has been shown to induce anchorage-independent growth at frequencies consistent with mutation at a single gene locus (6) (7) (8) , or perhaps pool of loci, any locus of which is permissive in its mutant form. Mutagen-induced acquisition of anchorage-independent growth in many aneuploid immortal rodent cell lines has been shown to correlate well with acquisition of tumorigenic growth (7, (9) (10) (11) , whereas in diploid primary human fibroblasts, mutagen treatment has been shown to induce anchorage-independent cell populations (8, (12) (13) (14) that do not yield progressively growing tumors (15) (16) (17) , and, consistent with this, the anchorageindependent cell clones senesce at passage levels similar to non-anchorage-independent cell clones (17) . When neoplastic transformation is viewed in the context of a multiple-step transition from normal to neoplastic cell (18) , mutageninduced anchorage independence is likely to represent one of these discrete steps, where this acquired phenotype is related mechanistically to the final tumorigenic state.
Our interest here was to determine whether mutageninduced soft agar growth could be assigned to an activating mutation at a specific human gene. We found that mutagen treatment induced soft agar growth in human fibroblasts and that cellular DNA from the majority of the anchorageindependent clones could also tumorigenically transform NIH 3T3 cells. In two clones, an activated human HRAS oncogene was identified in the NIH 3T3 tumor cells; in addition, in the majority of the anchorage-independent human clones, an as yet to be identified gene or genes was responsible for the observed human cell anchorage independence and associated NIH 3T3 cell transformation.
MATERIALS AND METHODS
Cells, Mutagen Treatment, Soft Agar Cloning. A diploid human foreskin fibroblast culture (25sk) was initiated in our laboratory as described (19) , and these cells (passage 2-3, 2 x 106 cells per group, 11 replicate groups) were treated with an LD70 (0.24 ,uM) of (±+)7f3,8a-dihydroxy-9a,10a-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene (anti-diol-epoxide) or solvent control as described (19) . Anchorage-independent clonal cell populations were selected in agar as described in detail elsewhere (20) . Anchorage-independent colonies (162 colonies; diameter, >75 ,um) were picked, and 17 of these clonal populations were expanded and used for genomic DNA isolation.
NIH 3T3 Transfections and Nude Mouse Injections. DNA transfection was done by the calcium phosphate coprecipitation method as described (21) . NIH 3T3 cells (7.5 DNA Amplification. Amplification of DNA was done by the described procedure (24) . Briefly, a 50-plI reaction containing 1 ,g of genomic DNA; 10% dimethylsulfoxide; 2 ,ug of each primer; 33 ,uM each dATP, dCTP, dGTP, and dTTP; 67 mM Tris-HCI (pH 8.8); 16.6 mM ammonium sulfate; 6.7 mM MgCl2; 10 mM 2-mercaptoethanol; 6.7 ,uM EDTA was incubated at 95°C for 7 min. After allowing 5 min at 60°C to anneal the primers, 1 unit of DNA polymerase from Thermus aquaticus (New England Biolabs) was added and the primers were extended at 70°C for 5 min. Subsequently, denaturation was done at 93°C for 1.5 min, annealing was at 60°C for 2 min, and polymerization was at 70°C for 2 min. After 10 cycles, an additional unit of DNA polymerase was added. After 25 cycles, primers (2 ug each) and dNTPs (33 uM each) were added. Typically, 40 cycles were done, and the desired product [144-base-pair (bp) fragment] was purified on a 3% agarose (Nusieve) or 5% polyacrylamide gel. The fragment was 32P end-labeled and sequenced by Maxam and Gilbert reactions (25) .
RESULTS
Anti-Diol-Epoxide-Induced Anchorage Independence in Diploid Human Fibroblasts. Eleven replicate groups of 25sk diploid human fibroblasts were treated with a LD70 (dose lethal to 70% of treated cells) (0.24 ttM) of anti-diol-epoxide, a dose that induces 6-thioguanine-resistant mutants at a measurable frequency ( 5 x 10-4) in these same cells (19, 20) . The surviving cells in the treatment groups were independently carried and seeded into soft agar to select anti-diolepoxide-induced anchorage-independent cell populations.
After 4 weeks growth, all colonies >75 Aum in diameter (range, 75-140 ,um) were scored. When corrected for plating efficiencies and the original anti-diol-expoxide-induced cytotoxicity, the agar colony frequency was 113 colonies per 105 normalized viable cells (11 x 10-4) in the mutagentreated groups, which is 22-fold higher than background (20) . A large number of agar colonies (162 colonies) >75 ,m in diameter were individually picked from the 11 treatment groups with a sterile micropipette and micromanipulator and then were individually expanded. Of these, 17 colonies that grew well were expanded to the level of 200-300 x 106 cells. 
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NT NT NIH 3T3 cells were transfected with genomic DNA isolated from anchorage-independent human fibroblast clones (19K-29L, column 1) along with the selectable marker pSV2neo (see Materials and Methods). After selection in G418, all drug-resistant colonies in each transfection group (typically 2500-4000 G418-resistant colonies per group) were pooled and injected (typically 5 x 106 cells per site, three flank sites; 10 x 106 cells per site, three flank sites) into nude mice. The negative tumor control involved transfection of NIH 3T3 cells with DNA from the untreated human fibroblasts (25sk) along with pSV2neo, G418 selection, and injection; no tumors were observed through 100 days of observation. Positive tumor controls consisted of pSV2neo cotransfection of NIH 3T3 cells with either plasmid DNA [pEJ6.6, HRAS codon 12 mutation (26); pSM-1, overexpressed human SIS gene (27) ] or cellular DNA (T24, HRAS codon 12 mutation; HT1080, NRAS codon 61 mutation) that contained known oncogenes. (Fig. 1) . Transfection of DNA from untreated human fibroblasts along with pSV2neo yielded G418-resistant NIH 3T3 cells that failed to produce tumors at 8 of 8 injection sites through 100 days of postinjection observation. The DNAs isolated from anti-diol-epoxide-induced anchorage-independent human cell colonies showed a range of transforming potentials (Fig. 1) ; the tumor growth rates were nearly the same in all groups, irrespective of the tumor latency or multiplicity. In aggregate, 11 of 17 DNAs from anti-diolepoxide-induced anchorage-independent human cell populations contain transforming sequences that, after transfection into NIH 3T3 cells, induced at least one tumor. The observation of no tumors in the negative control group (at eight of eight injection sites) increases the likelihood that those single tumors observed in some of the experimental DNA groups were in fact induced by the transfected human DNA.
Detection of Human RAS Genes in DNA from NIH 3T3 Tumor Cells. To date, most of the oncogenes detected by NIH 3T3 focus or tumorigenicity assays have been members of the RAS gene family. In addition, the mutagen we used, anti-diol-epoxide, has been shown to preferentially induce GC --TA transversions in the Escherichia coli lacIgene (29) , mutations identical to those originally observed in codon 12 of the human EJ/T24 HRAS oncogene (26 Fig. 2B , the expected 6.6-kb human HRAS fragment was observed in the three human DNA controls (25sk, T24, T24/3T3). Two NIH 3T3 tumor DNAs (groups 20H and 21A) containing DNA from anchorage-independent colonies also showed the characteristic human 6.6-kb hybridizing fragment. None of the characteristic human KRAS (Fig. 2C) or NRAS (Fig. 2D) bands were detectable in the NIH 3T3 tumor cell DNA digests. When 1-11) are labeled with the original agar colony group name (see Table 1 ). HindIII-digested A phage DNA was used as the size standard; indicated sizes are in kbp.
Cell Biology: Stevens et al.
-mdbm la-m-.m moo cells were analyzed by electrophoresis (data not shown), groups 20H/3T3 and 21A/3T3 showed slow-migrating p21 proteins, consistent with a codon 12 mutation, as did the T24 and T24/3T3 controls.
Sequence Analysis of Codon 12 HRAS Mutation in Clone 21A. Sequence analysis of the HRAS alleles in the original human clone 21A was done for two reasons: (i) to verify that the activating HRAS mutation had been induced by anti-diolepoxide in the original human cells and not acquired during NIH 3T3 transfection; and (ii) to identify the nucleotide position and type of base change in codon 12 that had been induced by anti-diol-epoxide, to determine whether the base change was like or unlike the many codon 12 mutations that have been described in human lung and bladder tumors (30) , tumors whose etiology has been presumed to be related to carcinogen exposure. Before sequence analysis, a portion of exon 1 from the HRAS gene was enzymatically amplified (24) as shown in Fig. 3A and B. Primer 1 showed a 75-90% base mismatch with the two other published 5' flanking sequences for RAS genes (KRASJ, KRASI pseudogene, respectively; GenBank database), while primer 2 showed 9%, 17%, or 78% base mismatch for the other RAS genes (KRAS2, NRAS, KRASI pseudogene, respectively); these degrees of primer mismatch indicate that the 144-bp amplified sequence represents specific amplification of the two HRAS alleles in clone 21A. After purification and end-labeling, a portion of the 144-bp fragment was sequenced (Fig. 3C) . The sequence of codons 2-27 was identical to that previously published (26) A codon 2 3 4 5 6 7 8 except for the second guanine band in codon 12. The intensity ofthis guanine band was 52% ofthe mean intensity ofthe four other guanine bands of codons 12 and 13, while the intensity of the thymine/cytosine band at this same position was 48% of the intensity for the thymine/cytosine band present in 
